MRK · Merck & Co Inc
Price
Snapshot
50 fields · last close| Market Cap | $360.1B |
| P/E | 113.48 |
| Float | 2.47B |
| Beta | 0.12 |
| Volatility | 5.0% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Mega cap |
| Macro sensitivity | Low |
| Clavix score | 75.1 |
| Price | 144.59 |
| Change | −0.93% |
| Prev Close | 145.95 |
| Open | 146.96 |
| Day Low | 145.61 |
| Day High | 147.79 |
| Avg Vol | 9 |
| Avg $ Vol | $1.36B |
| 52W High | 156.92 |
| 52W Low | 82.01 |
| 52W Pos | 83.5% |
| From High | −7.86% |
| From Low | +76.31% |
| Max DD 1Y | −11.90% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | −0.79% |
| SMA 50 | −0.37% |
| SMA 200 | +15.79% |
| RSI (14) | 51.9 |
| Vol 30D | 24.6% |
| Vol 90D | 33.2% |
| 1Y Range | 82–157 |
| Daily bars | 536 |
| Perf Week | +0.24% |
| Perf Month | −0.82% |
| Perf Quarter | +17.32% |
| Perf Half Y | +22.57% |
| Perf Year | +73.52% |
| Perf YTD | +35.83% |
| Prev Day | −0.93% |
| Clavix | B+ |
| Debt / Eq | 0.34 |
| Curr Ratio | 1.54 |
| Int Cover | 0.4× |
| FCF Margin | 19.0% |
| Rev Growth | +1.3% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 9 / 14 |
What MRK does
Merck & Co., Inc. operates as a healthcare company worldwide.
It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.
It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets.
The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Clavix risk grade
regraded every trading dayMRK grades B+, 75.1 of 100. Steadiest on Macro Resilience (63), most exposed on Sector Resilience (53, mixed). 0 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 9 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| MRK | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.12 | 0.44 |
| Volatilityannualized | 5.0% | 10.9% |
| Max drawdown, past yearworst peak-to-trough fall | −11.9% | — |
| Typical daily movemedian absolute daily change | 1.04% | — |
| Days beyond ±3%of the last 252 sessions | 22 (9%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MRK | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.12 | 0.44 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MRK | |
|---|---|
| 1 week | +0.2% |
| 1 month | −0.8% |
| Year to date | +35.8% |
| 1 year | +73.5% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MRK | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 28 Sep |
| Average score0 most bearish, 100 most bullish | 58 |
| Bullish · bearisharticles above 60 · below 40 | 19 · 8 |
| Directionarticles whose tone is improving vs worsening | 19 ↑ 8 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| MRK | |
|---|---|
| Revenue growthyear over year | +1.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openCantor Fitzgerald Investment Advisors L.P. cut its Merck & Co. (MRK) holdings by 65.9% during the third quarter, leaving it with 37,907 shares, according to its latest 13F filing with the SEC.
Merck and Moderna executives said at the STAT Summit that the two companies still have much to explore after initial success pairing Merck's Keytruda immunotherapy with Moderna's personalized mRNA cancer vaccines, which are designed to target a patient's specific tumor.
The article notes Merck trades at 5.5 times its annual sales versus 3.1 times for the S&P 500, and points out that management's emphasis on the August 4, 2026 call had shifted away from GARDASIL vaccine conditions in China, which executives had flagged as challenging on the February 2025 fiscal Q4 2024 call. The article does not specify what management now emphasizes.
Merck announced that Paul J. Diaz, managing partner at Cressey & Company, will join its Board of Directors effective November 1, 2026, expanding the board to 14 members. He will stand for formal election by shareholders in May 2027.
Merck announced it will present first-time results from three pivotal Phase 3 clinical trials at the ESMO Congress 2026 in Madrid (Oct 23-27), along with more than 90 additional abstracts covering over 20 tumor types from its oncology pipeline and existing portfolio.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | A- | $615.9B | 38.26 | 0.21 | Compare |
| AZN | AstraZeneca PLC | B+ | $196.9B | 25.12 | 1.27 | Compare |
| PFE | Pfizer Inc | A- | $168.6B | 38.91 | 0.31 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $122.1B | 13.15 | 0.19 | Compare |
| LLY | Eli Lilly and Co | B | $1.18T | 44.30 | 0.42 | Compare |
| RPRX | Royalty Pharma PLC | A | $35.06B | 43.01 | 0.39 | Compare |
| ZTS | Zoetis Inc | B+ | $31.87B | 12.55 | 0.70 | Compare |
| VTRS | Viatris Inc | B+ | $21.43B | — | 0.89 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.